Dawn C. Schwenke

7.2k total citations · 3 hit papers
83 papers, 5.8k citations indexed

About

Dawn C. Schwenke is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Dawn C. Schwenke has authored 83 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Surgery and 20 papers in Molecular Biology. Recurrent topics in Dawn C. Schwenke's work include Diabetes, Cardiovascular Risks, and Lipoproteins (19 papers), Adipokines, Inflammation, and Metabolic Diseases (16 papers) and Antioxidant Activity and Oxidative Stress (14 papers). Dawn C. Schwenke is often cited by papers focused on Diabetes, Cardiovascular Risks, and Lipoproteins (19 papers), Adipokines, Inflammation, and Metabolic Diseases (16 papers) and Antioxidant Activity and Oxidative Stress (14 papers). Dawn C. Schwenke collaborates with scholars based in United States, Italy and United Kingdom. Dawn C. Schwenke's co-authors include T E Carew, Daniel Steinberg, Peter D. Reaven, Alan M. Fogelman, Norbert Leitinger, Andrew D. Watson, Ganesamoorthy Subbanagounder, Judith A. Berliner, Kym F. Faull and Richard W. St. Clair and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Dawn C. Schwenke

82 papers receiving 5.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.

1987 877 citations Dawn C. Schwenke et al. profile →
Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo

1997 659 citations Andrew D. Watson, Norbert Leitinger et al. Journal of Biological Chemistry profile →
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

2011 523 citations Ralph A. DeFronzo, Devjit Tripathy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn C. Schwenke United States	35	2.0k	1.6k	1.5k	1.2k	1.1k	83	5.8k
Francisco Blanco‐Vaca Spain	41	1.3k 0.7×	1.5k 0.9×	2.3k 1.5×	355 0.3×	454 0.4×	178	5.5k
Helena Gylling Finland	50	1.8k 0.9×	2.1k 1.3×	4.7k 3.2×	597 0.5×	620 0.6×	225	8.0k
Rodolfo Paoletti Italy	43	1.1k 0.6×	2.2k 1.4×	3.7k 2.5×	453 0.4×	827 0.7×	132	8.7k
Luigi Iuliano Italy	47	445 0.2×	1.7k 1.1×	1.7k 1.1×	1.1k 0.9×	701 0.6×	133	5.7k
Takanori Matsui Japan	54	3.7k 1.9×	2.3k 1.4×	951 0.6×	275 0.2×	770 0.7×	252	9.2k
Günther Jürgens Austria	37	764 0.4×	1.7k 1.1×	1.9k 1.3×	3.5k 2.9×	1.7k 1.5×	105	7.5k
Luciano Cominacini Italy	40	647 0.3×	1.2k 0.8×	713 0.5×	656 0.5×	1.2k 1.0×	127	4.8k
Anatol Kontush France	55	4.6k 2.3×	3.0k 1.9×	4.2k 2.9×	1.4k 1.1×	888 0.8×	163	11.7k
Betty A. Maddux United States	38	2.3k 1.2×	3.2k 2.0×	1.3k 0.9×	397 0.3×	494 0.4×	83	7.4k
Toyoshi Inoguchi Japan	46	1.9k 1.0×	3.0k 1.9×	1.3k 0.9×	278 0.2×	695 0.6×	147	8.3k

Countries citing papers authored by Dawn C. Schwenke

Since Specialization

Citations

This map shows the geographic impact of Dawn C. Schwenke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn C. Schwenke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn C. Schwenke more than expected).

Fields of papers citing papers by Dawn C. Schwenke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn C. Schwenke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn C. Schwenke. The network helps show where Dawn C. Schwenke may publish in the future.

Co-authorship network of co-authors of Dawn C. Schwenke

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn C. Schwenke. A scholar is included among the top collaborators of Dawn C. Schwenke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn C. Schwenke. Dawn C. Schwenke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Yueming, Jeremy D. Furtado, Dean Billheimer, et al.. (2024). Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study. Diabetes Care. 47(12). 2214–2222. 2 indexed citations

Saremi, Aramesh, Scott K. Howell, Dawn C. Schwenke, et al.. (2017). Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study. Diabetes Care. 40(4). 591–598. 72 indexed citations

Tripathy, Devjit, Dawn C. Schwenke, George A. Bray, et al.. (2016). Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW. The Journal of Clinical Endocrinology & Metabolism. 101(5). 2056–2062. 35 indexed citations

Espinoza, Sara, Chen-Pin Wang, Devjit Tripathy, et al.. (2016). Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. AGE. 38(5-6). 485–493. 12 indexed citations

Koška, Juraj, Michelle Sands, James Liu, et al.. (2015). Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. Diabetes. 64(7). 2624–2635. 143 indexed citations

Tripathy, Devjit, Jeff E. Cobb, Walter Gall, et al.. (2015). A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study. The Journal of Clinical Endocrinology & Metabolism. 100(5). 1855–1862. 26 indexed citations

Schwenke, Dawn C., et al.. (2015). Weight Loss Promotes Nonbariatric Surgery Medical Clearance.. PubMed. 32(4). 20–25. 1 indexed citations

Oran, Paul E., Olgica Trenchevska, Dobrin Nedelkov, et al.. (2014). Parallel Workflow for High-Throughput (>1,000 Samples/Day) Quantitative Analysis of Human Insulin-Like Growth Factor 1 Using Mass Spectrometric Immunoassay. PLoS ONE. 9(3). e92801–e92801. 43 indexed citations

Schwenke, Dawn C., John P. Foreyt, Edgar R. Miller, Rebecca S. Reeves, & Mara Z. Vitolins. (2013). Plasma concentrations of trans fatty acids in persons with type 2 diabetes between September 2002 and April 2004. American Journal of Clinical Nutrition. 97(4). 862–871. 13 indexed citations

10.

Belalcazar, L. Maria, Christie M. Ballantyne, Wei Lang, et al.. (2011). Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes. Arteriosclerosis Thrombosis and Vascular Biology. 31(7). 1689–1695. 45 indexed citations

11.

Belalcazar, L. Maria, David M. Reboussin, Steven M. Haffner, et al.. (2010). A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change. Diabetes Care. 33(11). 2297–2303. 84 indexed citations

12.

Schwartz, Eric A., et al.. (2010). Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 212(1). 217–222. 152 indexed citations

13.

DeFronzo, Ralph A., MaryAnn Banerji, George A. Bray, et al.. (2009). Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocrine Disorders. 9(1). 17–17. 64 indexed citations

14.

Belalcazar, L. Maria, David M. Reboussin, Steven M. Haffner, et al.. (2009). Marine ω-3 Fatty Acid Intake. Diabetes Care. 33(1). 197–199. 24 indexed citations

15.

Page, Jeffrey C., et al.. (2004). Retrospective Analysis of Negative Pressure Wound Therapy in Open Foot Wounds with Significant Soft Tissue Defects. Advances in Skin & Wound Care. 17(7). 354–364. 37 indexed citations

16.

Yang, Zheng, Xiandeng Hou, Bradley T. Jones, et al.. (2002). Determination of calcium, iron and magnesium in rabbit arteries by inductively coupled plasma atomic emission spectrometry. Microchemical Journal. 72(1). 49–54. 8 indexed citations

17.

Schwenke, Dawn C.. (2000). Metabolic evidence for sequestration of low-density lipoprotein in abdominal aorta of normal rabbits. American Journal of Physiology-Heart and Circulatory Physiology. 279(3). H1128–H1140. 6 indexed citations

18.

Watson, Andrew D., Norbert Leitinger, Mohamad Navab, et al.. (1997). Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo. Journal of Biological Chemistry. 272(21). 13597–13607. 659 indexed citations breakdown →

19.

Schwenke, Dawn C. & Stephen R. Behr. (1994). Inhibition of atherosclerosis in hypercholesterolemic rabbits by combination of nutrient antioxidants. Atherosclerosis. 109(1-2). 77–77. 1 indexed citations

20.

Schwenke, Dawn C. & Donald B. Zilversmit. (1989). The arterial barrier to lipoprotein influx in the hypercholesterolemic rabbit. Atherosclerosis. 77(2-3). 91–103. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact